99 related articles for article (PubMed ID: 20007676)
1. Second chances in mineral metabolism.
Wolf M
Clin J Am Soc Nephrol; 2010 Jan; 5(1):1-3. PubMed ID: 20007676
[No Abstract] [Full Text] [Related]
2. FGF23: a key player in mineral and bone disorder in CKD.
Komaba H; Fukagawa M
Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
[TBL] [Abstract][Full Text] [Related]
3. Mineral and bone metabolism in dialysis: towards unified patient care?
Pelletier S; Fouque D
Nephrol Dial Transplant; 2011 Jan; 26(1):7-9. PubMed ID: 21106773
[No Abstract] [Full Text] [Related]
4. [Water and salt metabolism in chronic uremigenic nephropathies].
Mioni G; Cristinelli L; Messa PG; Montanaro D
G Clin Med; 1980 May; 61(5):332-41. PubMed ID: 7450354
[No Abstract] [Full Text] [Related]
5. Nutrition in renal disease.
Richards P; Ell S
Hum Nutr Clin Nutr; 1982; 36(2):103-13. PubMed ID: 7050028
[No Abstract] [Full Text] [Related]
6. With or without the kidney: the role of FGF23 in CKD.
Fukagawa M; Kazama JJ
Nephrol Dial Transplant; 2005 Jul; 20(7):1295-8. PubMed ID: 15840677
[No Abstract] [Full Text] [Related]
7. The bone-renal axis in early chronic kidney disease: an emerging paradigm.
Danziger J
Nephrol Dial Transplant; 2008 Sep; 23(9):2733-7. PubMed ID: 18469306
[No Abstract] [Full Text] [Related]
8. Lipoprotein metabolism and lipid management in chronic kidney disease.
Kwan BC; Kronenberg F; Beddhu S; Cheung AK
J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943
[No Abstract] [Full Text] [Related]
9. The role of fibroblast growth factor 23 in renal disease.
Jonsson KB
Nephrol Dial Transplant; 2005 Mar; 20(3):479-82. PubMed ID: 15735238
[No Abstract] [Full Text] [Related]
10. [Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis].
Goicoechea MA
Nefrologia; 2004; 24 Suppl(6):142-60, 187-235. PubMed ID: 15696904
[No Abstract] [Full Text] [Related]
11. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
12. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
13. [Antihypertensive therapy in patients with 4 and 5 stage chronic kidney disease undergoing periodic dialysis].
Goicoechea MA
Nefrologia; 2004; 24 Suppl(6):161-71, 187-235. PubMed ID: 15696905
[No Abstract] [Full Text] [Related]
14. Did the release of KDOQI guidelines really improve the control of bone mineral metabolism in hemodialysis patients?
Massart A; Wissing KM; Debelle FD
Am J Kidney Dis; 2007 Oct; 50(4):686; author reply 686-7. PubMed ID: 17900471
[No Abstract] [Full Text] [Related]
15. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
Inaguma D; Tatematsu M
Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
[TBL] [Abstract][Full Text] [Related]
16. How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?
Wyne KL; Fishbane S; Block GA; Warburton K; Berns JS; Neu AM; Warady BA
Semin Dial; 2006; 19(1):8-24. PubMed ID: 16423174
[No Abstract] [Full Text] [Related]
17. Homocysteine in renal disease.
Ducloux D; Motte G; Chalopin JM
Clin Lab; 2000; 46(3-4):141-51. PubMed ID: 10791121
[No Abstract] [Full Text] [Related]
18. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
Wanner C; Drechsler C; Krane V
J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
[TBL] [Abstract][Full Text] [Related]
19. Which is the best way for estimating transferrin saturation?
Eleftheriadis T; Liakopoulos V; Antoniadi G; Stefanidis I
Ren Fail; 2010; 32(8):1022-3. PubMed ID: 20722575
[No Abstract] [Full Text] [Related]
20. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
